Literature DB >> 11034382

Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles.

D Haddad1, J Ramprakash, M Sedegah, Y Charoenvit, R Baumgartner, S Kumar, S L Hoffman, W R Weiss.   

Abstract

Plasmid-encoded GM-CSF (pGM-CSF) is an adjuvant for genetic vaccines; however, little is known about how pGM-CSF enhances immunogenicity. We now report that pGM-CSF injected into mouse muscle leads to a local infiltration of potential APCs. Infiltrates reached maximal size on days 3 to 5 after injection and appeared in several large discrete clusters within the muscle. Immunohistological studies in muscle sections from mice injected with pGM-CSF showed staining of cells with the macrophage markers CD11b, Mac-3, IA(d)/E(d) and to the granulocyte marker GR-1 from day 1 through day 14. Cells staining with the dendritic cell marker CD11c were detected only on days 3 to 5. Muscles injected with control plasmids did not stain for CD11c but did stain for CD11b, Mac-3, IA(d)/E(d), and GR-1. No staining was observed with the APC activation markers, B7.1 or CD40, or with markers for T or B cells. These findings are consistent with the infiltrating cells in the pGM-CSF-injected muscles being a mixture of neutrophils, macrophages, and immature dendritic cells and suggest that the i.m. APCs may be enhancing immune responses to coinjected plasmid Ags. This hypothesis is supported by data showing that 1) separation of injections with pGM-CSF and Ag-expressing plasmid into different sites did not enhance immune responses and 2) immune enhancement was associated with the presence of CD11c+ cells in the infiltrates. Thus, pGM-CSF enhancement may depend on APC recruitment to the i.m. site of injection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11034382     DOI: 10.4049/jimmunol.165.7.3772

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

Review 1.  Nucleic acid vaccines: tasks and tactics.

Authors:  B S McKenzie; A J Corbett; J L Brady; C M Dyer; R A Strugnell; S J Kent; D R Kramer; J S Boyle; A M Lew
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Induction of protective immunity against Schistosoma mansoni via DNA priming and boosting with the large subunit of calpain (Sm-p80): adjuvant effects of granulocyte-macrophage colony-stimulating factor and interleukin-4.

Authors:  Afzal A Siddiqui; Troy Phillips; Hugues Charest; Ron B Podesta; Martha L Quinlin; Justin R Pinkston; Jenny D Lloyd; Michelle Paz; Rachael M Villalovos; Janet Pompa
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

3.  Dynamics of cytokine/chemokine responses in intestinal CD4+ and CD8+ T Cells during Acute Simian Immunodeficiency Virus Infection.

Authors:  Carys S Kenway-Lynch; Arpita Das; Diganta Pan; Andrew A Lackner; Bapi Pahar
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

4.  In-situ crosslinking hydrogels for combinatorial delivery of chemokines and siRNA-DNA carrying microparticles to dendritic cells.

Authors:  Ankur Singh; Shalu Suri; Krishnendu Roy
Journal:  Biomaterials       Date:  2009-06-27       Impact factor: 12.479

Review 5.  Combinatorial drug delivery approaches for immunomodulation.

Authors:  Joshua M Stewart; Benjamin G Keselowsky
Journal:  Adv Drug Deliv Rev       Date:  2017-05-19       Impact factor: 15.470

6.  Cytokine/Chemokine responses in activated CD4+ and CD8+ T cells isolated from peripheral blood, bone marrow, and axillary lymph nodes during acute simian immunodeficiency virus infection.

Authors:  Carys S Kenway-Lynch; Arpita Das; Andrew A Lackner; Bapi Pahar
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

Review 7.  DNA vaccines: developing new strategies against cancer.

Authors:  Daniela Fioretti; Sandra Iurescia; Vito Michele Fazio; Monica Rinaldi
Journal:  J Biomed Biotechnol       Date:  2010-03-28

8.  The MIC3 gene of Toxoplasma gondii is a novel potent vaccine candidate against toxoplasmosis.

Authors:  Alaa Bassuny Ismael; Dalila Sekkai; Christine Collin; Daniel Bout; Marie-Noëlle Mévélec
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

9.  Effects of type I interferons on the adjuvant properties of plasmid granulocyte-macrophage colony-stimulating factor in vivo.

Authors:  Lizeng Qin; John R Greenland; Chikaya Moriya; Mark J Cayabyab; Norman L Letvin
Journal:  J Virol       Date:  2007-07-25       Impact factor: 5.103

10.  High Doses of GM-CSF Inhibit Antibody Responses in Rectal Secretions and Diminish Modified Vaccinia Ankara/Simian Immunodeficiency Virus Vaccine Protection in TRIM5α-Restrictive Macaques.

Authors:  Sunil Kannanganat; Linda S Wyatt; Sailaja Gangadhara; Venkatesarlu Chamcha; Lynette S Chea; Pamela A Kozlowski; Celia C LaBranche; Lakshmi Chennareddi; Benton Lawson; Pradeep B J Reddy; Tiffany M Styles; Thomas H Vanderford; David C Montefiori; Bernard Moss; Harriet L Robinson; Rama Rao Amara
Journal:  J Immunol       Date:  2016-09-28       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.